Oncology drug development is especially risky with only 5% of new compounds reaching market approval. The lack of patient-relevant, early-stage preclinical models that can be rapidly expanded for drug screening is contributing to this poor success rate.
Download this White Paper to discover
- The key patient-derived organoids (PDO or HUB Organoids) features which makes them best-in-class models for drug development
- How HUB Organoids are revolutionizing drug development by providing translatable and predictive in vitro pharmacology data
- How to predict patient response in the clinic by setting up prospective studies using HUB Organoids as patient avatars
- The evolution from genomic-led drug development to an integrated genomic and organoid screening-based approach